@Article{,
AUTHOR = {Graeme G. Duncan, Tom Corbett, Himu Lukka, 
Padraig Warde, Tom Pickles},
TITLE = {GU radiation oncologists consensus on bone  loss from androgen deprivation},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {13},
YEAR = {2006},
NUMBER = {1},
PAGES = {2962--2966},
URL = {http://www.techscience.com/CJU/v13n1/62949},
ISSN = {1488-5581},
ABSTRACT = {The majority of GU radiation oncologists in Canada 
attended a consensus meeting in November 2004. The 
topic of osteoporosis in men receiving androgen 
deprivation therapy (ADT) for prostate cancer was 
identified as a key theme. A chaired session with keynote 
speakers and review of the evidence took place followed 
by open debate. Participants were provided with 
background information. <br/>
Osteoporosis was defined as a T-score <= -2.5, but the 
importance of risk factors and clinical findings is noted. 
Dual DEXA is the current standard for assessment of 
bone density and relates well to fracture risk. The lifetime 
risk of fracture is 13% for men over the age of 50 years 
even without the influence of ADT. Lifestyle, dietary and supplementation advice are provided both to prevent and 
to manage osteoporosis. The role for prophylactic 
bisphosphonate therapy in men on ADT without 
osteoporosis has not been established. Follow-up DEXA 
scans are required to monitor density, risk and response 
to interventions. Fracture incidence and BMD should be 
considered in the trial design of studies involving 
prolonged ADT. Osteoporosis is a treatable condition and 
the oncologist should employ ADT with this knowledge. 
A follow-up e-mail survey was carried out regarding 
the consensus statement. Responses were received 
from 49 of the 69 attendees (71%), and overall there 
was an 89% agreement with the consensus statement. 
This is now adopted as national practice guidelines 
for radiation oncologists employed prolonged ADT in 
prostate cancer patients. },
DOI = {}
}